These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 8847547

  • 1. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF.
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [Abstract] [Full Text] [Related]

  • 2. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
    Kienzl E, Jellinger K, Stachelberger H, Linert W.
    Life Sci; 1999 Dec; 65(18-19):1973-6. PubMed ID: 10576448
    [Abstract] [Full Text] [Related]

  • 3. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
    Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MB.
    J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
    [Abstract] [Full Text] [Related]

  • 4. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
    Ben-Shachar D, Youdim MB.
    J Neural Transm Suppl; 1990 Sep; 29():251-8. PubMed ID: 2193109
    [Abstract] [Full Text] [Related]

  • 5. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB, Riederer P.
    J Neural Transm Suppl; 1993 Sep; 40():57-67. PubMed ID: 8294901
    [Abstract] [Full Text] [Related]

  • 6. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC.
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [Abstract] [Full Text] [Related]

  • 7. Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry.
    Biesemeier A, Eibl O, Eswara S, Audinot JN, Wirtz T, Pezzoli G, Zucca FA, Zecca L, Schraermeyer U.
    J Neurochem; 2016 Jul; 138(2):339-53. PubMed ID: 27121280
    [Abstract] [Full Text] [Related]

  • 8. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.
    Ben-Shachar D, Eshel G, Riederer P, Youdim MB.
    Ann Neurol; 1992 Jul; 32 Suppl():S105-10. PubMed ID: 1510367
    [Abstract] [Full Text] [Related]

  • 9. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
    Youdim MB, Ben-Shachar D, Riederer P.
    Acta Neurol Scand Suppl; 1989 Jul; 126():47-54. PubMed ID: 2618593
    [Abstract] [Full Text] [Related]

  • 10. Metals, oxidative stress and neurodegenerative disorders.
    Jomova K, Vondrakova D, Lawson M, Valko M.
    Mol Cell Biochem; 2010 Dec; 345(1-2):91-104. PubMed ID: 20730621
    [Abstract] [Full Text] [Related]

  • 11. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
    Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB.
    J Neural Transm Suppl; 1995 Dec; 46():297-314. PubMed ID: 8821067
    [Abstract] [Full Text] [Related]

  • 12. Iron, melanin and dopamine interaction: relevance to Parkinson's disease.
    Ben-Shachar D, Youdim MB.
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):139-50. PubMed ID: 8416600
    [Abstract] [Full Text] [Related]

  • 13. XANES spectroscopy of a single neuron from a patient with Parkinson's disease.
    Yoshida S, Ektessabi A, Fujisawa S.
    J Synchrotron Radiat; 2001 Mar 01; 8(Pt 2):998-1000. PubMed ID: 11513007
    [Abstract] [Full Text] [Related]

  • 14. Oxidative stress: a role in the pathogenesis of Parkinson's disease.
    Götz ME, Freyberger A, Riederer P.
    J Neural Transm Suppl; 1990 Mar 01; 29():241-9. PubMed ID: 2193108
    [Abstract] [Full Text] [Related]

  • 15. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM.
    J Neural Transm Park Dis Dement Sect; 1994 Mar 01; 7(2):83-100. PubMed ID: 7710667
    [Abstract] [Full Text] [Related]

  • 16. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB, Ben-Shachar D, Riederer P.
    J Neural Transm Suppl; 1994 Mar 01; 43():113-22. PubMed ID: 7884393
    [Abstract] [Full Text] [Related]

  • 17. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB, Ben-Shachar D, Riederer P.
    Mov Disord; 1993 Mar 01; 8(1):1-12. PubMed ID: 8419792
    [Abstract] [Full Text] [Related]

  • 18. Impaired iron homeostasis in Parkinson's disease.
    Double KL, Gerlach M, Youdim MB, Riederer P.
    J Neural Transm Suppl; 2000 Mar 01; (60):37-58. PubMed ID: 11205155
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxidative stress in Parkinson's disease.
    Jiang D, Shi S, Zhang L, Liu L, Ding B, Zhao B, Yagnik G, Zhou F.
    ACS Chem Neurosci; 2013 Sep 18; 4(9):1305-13. PubMed ID: 23823941
    [Abstract] [Full Text] [Related]

  • 20. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease.
    Zhang F, Dryhurst G.
    J Med Chem; 1994 Apr 15; 37(8):1084-98. PubMed ID: 7909337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.